Consumption of hipolipidemics in the Czech Republic in 2000–2007
Authors:
R. Bartas 1; J. Kolář 2
Authors‘ workplace:
Lékárna Aqua, Karviná
1; Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav aplikované farmacie
2
Published in:
Čes. slov. Farm., 2008; 57, 244-248
Category:
Original Articles
Overview
Hypolipidemics are a group of pharmaceuticals with an expressive portion on pharmaceuticals costs. Analysis of their consumption has been an object of repeated studies in our republic as well abroad. The present data on hypolipidemic drug utilization in 2000–2007 were obtained from the database of the State Institute of Drug Control. Utilization was expressed in defined daily doses (DDD) according to the ATC/DDD system, costs in Czech crowns. Utilization was expressed in relative values – DDD per 1 000 inhabitants per day (DID). The utilization of fibrates in the period under study is unchanged. The utilization of statins increased from 9.4 DID (2000) to 100 DID (2007). The maximal expenditures on hypolipidemic therapy were observed in 2005 (3 thousand million CZK). Statins are on the forefront of sales of medicines in the CR (2003–2006 – 1th place simvastatin, 2007 – 1th place atorvastatin (1th place in the world since 2001)).
Key words:
drug utilization – hypolipidaemics – statins – fibrates – ezetimibe
Sources
1. Zdravotnická ročenka ČR 2006. Praha, ÚZIS ČR, 2007, 264 s.
2. Zemřelí 2006. Praha, ÚZIS ČR, 2007, 104 s.
3. Hospitalizovaní v nemocnicích ČR 2006., Praha, ÚZIS ČR, 2007, 150 s.
4. Češka, R.: Remedia, 2006; 3, 261–267.
5. Strnad, L., Práznovcová, L.: Zdravotnictví v České republice, 2001; 4, 151–154.
6. Pavelková, R., Sobolová, L., Urbánek, K.: Klin. Farmakol. Farm., 2005; 19, 142–145.
7. Prokeš, M.: Zdravotnictví a finance, 2007; 2, 3–14.
8. Češka, R.: Kap. Kardiol., 2006; 8, 22–25.
9. Bultas, J.: Zdravotnictví a finance, 2007; 2, 19.
10. Walley, T., Folino-Gallo, P., Spephens, P., Van Ganse, E.: Br. J. Clin. Pharmacol., 2005; 60, 543–551.
11. Chen, T., Lin, S., Chen, L. et al.: J. Chin. Med. Assoc., 2003; 66, 39–45.
12. Sobolová, L.: Klin. Farmakol. Farm., 2005; 19, 22–26.
13. Pfizer ukončil vývoj léku na cholesterol. [on line]., [cit. 2008-04-15]. Dostupný z www: <http://www.medical-tribune.cz/aktualita/1942>
14. Štulc, T.: Lékařské listy, 2008; 10, 30–31.
15. Bultas, J., Karetová, D.: Pace News, 2004; 3, 1–4.
16. Teeling, M., Bennett, K., Feely, J.: Br. J. Clin. Pharmacol., 2004; 59, 227–232.
17. First Head to Head Study Comparing Crestor and Lipitor Effects on the Treatment of Atherosclerosis. [on line]., [cit. 2008-06-05]. Dostupný z www: <http://www. medicalnewstoday.com/articles/94051.php>
18. Lesná, M.: Zdravotnické noviny, 2008; 20, 14.
19. Bultas, J.: Interní medicína, 2006; 7–8, 314–322.
20. Kolář, J., Bartas, R.: Česká a slovenská farmacie, 2007; 56, 30–36.
21. World Health Statistics 2008. World Health Organization 2008 [on line]., [cit. 2008-09-10]. Dostupný z www: <http://www.who.int/entity/whosis/whostat/EN_WHS08_Full.pdf>
22. U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent. [on line]., [cit. 2008-08-17]. Dostupný z www: <http://findarticles.com/p/ articles/mi_m0EIN/is_2008_April_30/ai_n25364225>
23. Pfizer wins first round in Lipitor patent fight. [on line]., [cit. 2008-08-17]. Dostupný z www: <http://www. managingip.com/Article/1258148/Pfizer-wins-first-round-in-Lipitor-patent-fight.html>
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2008 Issue 6
Most read in this issue
- Possible effects on the liberation of alaptid from dermal semisolid preparations
- Studies of local anesthetics Part 185: Thermodynamic parameters of heptacainium chloride in the solution of NaBr
- Optimization of the extraction method for the determination of methadone and its metabolite EDDP in urine by gas chromatography
- The effect of lipophilic carrier concentration on hydrophilic-lipophilic matrix systems characteristics